CCL2 and neoplasm: A preclinical study in hepatocellular carcinoma assessing the blockade of CCL2/CCR2 with the CCR2 antagonist RDC018 revealed hindered tumor growth and metastasis, reduced postsurgical recurrence, and prolonged survival [100].